Ex-GSK China researchers hit back
This article was originally published in Scrip
The Chinese GlaxoSmithKline scientist who resigned in relation to alleged "misrepresentation of data" in a leading science journal has claimed not only that the data were authentic and reproducible but has also suggested that the internal investigation by the pharma firm may have been unbalanced.
You may also be interested in...
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
The randomized trial will evaluate the ability of the Reveal LINQ insertable monitor to help physicians prevent the progression of heart failure.
The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.